Lilly Furthers Precision Cancer Ambitions With Foghorn Collaboration
Building on its Loxo Oncology unit, Lilly teams with Foghorn to target cancers caused by BRG1 mutations, about 5% of all tumors, including 10% of NSCLC patients. Merck & Co. teamed up with Foghorn in 2020.
You may also be interested in...
A Phase I clinical trial of Foghorn’s FHD-286, which was placed on a partial hold in May after one death, is on a full hold now that multiple deaths may be attributed to differentiation syndrome.
The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.